CA
DAWN

Continuum Advisory’s Day One Biopharmaceuticals DAWN Stock Holding History

Continuum Advisory’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,058
Closed -$13.4K – 1743
2024
Q4 		$13.4K Hold
1,058
– – ﹤0.01% 931
2024
Q3 		$15.2K Sell
1,058
-282
-21% -$4.02K ﹤0.01% 899
2024
Q2 		$18.5K Hold
1,340
– – ﹤0.01% 806
2024
Q1 		$21.9K Buy
+1,340
New +$20.1K ﹤0.01% 759

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

Continuum Advisory's DAWN Position: Q1 2025 in Review

Continuum Advisory sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 1,058 shares — an estimated $13.4K sold.

Continuum Advisory first reported a position in DAWN in Q1 2024 and held it in 4 quarters. The position peaked at $21.9K in Q1 2024. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • Continuum Advisory reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 1,058 Day One Biopharmaceuticals shares in Q1 2025, an estimated $13.4K.
  • Continuum Advisory first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Continuum Advisory's Day One Biopharmaceuticals position peaked at $21.9K in Q1 2024.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.